









Markets
/
Stocks
/
nasdaq-rzlt
/

Rezolute Inc

RZLT

9.100USD

-0.220-2.36%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

791.66MMarket Cap

LossP/E TTM



Rezolute Inc

9.100

-0.220-2.36%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rezolute Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rezolute Inc's Score

Industry at a Glance

Industry Ranking

82 / 407

Overall Ranking

194 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

14.000

Target Price

+50.21%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Rezolute Inc Highlights

StrengthsRisks

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -9.29, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 83.92M shares, increasing 25.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.02M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.14.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.45, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Rezolute Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.36, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -9.29, which is -92.78% below the recent high of -0.67 and -8.02% above the recent low of -10.04.

Score

Industry at a Glance

Previous score

6.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 82/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.80, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Rezolute Inc is 14.00, with a high of 20.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

14.000

Target Price

+50.21%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Rezolute Inc

RZLT

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 8.96, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 10.16 and the support level at 7.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.08

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.041

Neutral

RSI(14)

52.076

Neutral

STOCH(KDJ)(9,3,3)

46.135

Sell

ATR(14)

0.599

Low Volatility

CCI(14)

-7.324

Neutral

Williams %R

59.758

Sell

TRIX(12,20)

0.463

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

9.452

Sell

MA10

9.361

Sell

MA20

9.013

Buy

MA50

8.463

Buy

MA100

6.939

Buy

MA200

5.422

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 92.40%, representing a quarter-over-quarter increase of 48.41%. The largest institutional shareholder is The Vanguard, holding a total of 4.02M shares, representing 4.43% of shares outstanding, with 15.51% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Federated Hermes Global Investment Management Corp.

14.03M

+24.43%

Fidelity Management & Research Company LLC

12.48M

+98.42%

Handok Inc

8.42M

+17.11%

Invus Public Equities LP

4.87M

The Vanguard Group, Inc.

Star Investors

4.02M

+69.34%

BlackRock Institutional Trust Company, N.A.

3.73M

+857.33%

Blackstone Alternative Asset Management, L.P.

3.56M

+104.06%

UBS Financial Services, Inc.

3.04M

+392.63%

Great Point Partners, LLC

3.03M

+264.14%

Marshall Wace LLP

2.89M

+56.43%

Risk Assessment

Currency: USD Updated: 2025-11-03

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is 0.08. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.